Cardiff Oncology, Inc. (CRDF)

[abracky]

TrovaGene (TROV) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Posted by Darrell McKinsey on Nov 24th, 2018
inShare

TrovaGene logoTrovaGene (NASDAQ:TROV) issued its quarterly earnings results on Wednesday, November 7th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.15, Fidelity Earnings reports. TrovaGene had a negative net margin of 3,066.39% and a negative return on equity of 139.55%. The business had revenue of $0.09 million for the quarter.

Shares of NASDAQ TROV opened at $0.69 on Friday. TrovaGene has a 1 year low of $0.65 and a 1 year high of $7.56. The firm has a market cap of $16.67 million, a P/E ratio of -0.11 and a beta of 0.14.
Get TrovaGene alerts:

A number of brokerages have issued reports on TROV. Maxim Group restated a “buy” rating on shares of TrovaGene in a research note on Monday, August 6th. Zacks Investment Research upgraded shares of TrovaGene from a “sell” rating to a “hold” rating in a research note on Tuesday, September 11th. Finally, ValuEngine upgraded shares of TrovaGene from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.